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Abstract 
This article reviews the literature pertinent to epigenetic changes, and in particular DNA methylation 
following Traumatic Brain Injury (TBI). TBI is a heterogeneous disease that is a major cause of death 
and long-term disability. The links between TBI and epigenetics, the process by which environmental 
factors alter gene expression without changing the underlying DNA sequence, is an expanding area of 
research that may have profound consequences for our understanding of the disease, and clinical care. 
There are various epigenetic changes that may occur as a direct result of TBI, including DNA 
methylation, histone modification, and changes in the levels of non-coding RNA. This review focuses 
on DNA methylation, its potential to alter the degree of injury, and the extent of recovery- including 
development of post-traumatic neurodegeneration, response to therapies, and the hereditable 
consequences of injury. The functional consequences of non-coding RNA and histone modifications 
are well described in the literature, but the mechanism by which these three mechanisms interact are 
often overlooked.  Here, we briefly describe the interaction of DNA methylation with the two other 
key epigenetic changes, and highlight key work being done to understand the functional relevance of 
those mechanisms. The field of epigenetics is rapidly advancing due to the advent of less invasive and 
more versatile methods for measuring epigenetic proteins and their functional impact on cells, 
however, the evidence specific to TBI is limited. This review identifies several important outstanding 
questions that remain from the work already conducted, and highlights directions for the future.  
 
 
  
The Effects of Traumatic Brain Injury on DNA Methylation 
 
Traumatic Brain Injury and Epigenetics 
Traumatic Brain Injury (TBI) is heterogeneous disease that is a major cause of death and long-term 
disability. Over half of serious head trauma survivors may be moderately to severely disabled one-year 
post-injury, while long-term impairments resulting from mild repetitive TBI are increasingly being 
recognized.1 Thus, with incidence rates of over 100 per 100,000 people, TBI is an important public 
health concern and requires further exploration.2 Recent efforts to understand disease pathophysiology 
have focused on epigenetics, the process by which environmental factors alter gene expression without 
changing the underlying DNA sequence.  Epigenetic changes are increasingly implicated in the 
pathophysiology following TBI (Figure 1),3 and may provide targets for therapy.  This review seeks to 
provide an introduction epigenetics, and focus on specific aspects of the process as a context for 
understanding emerging publications on epigenetic changes in TBI.  
 
Epigenetics 
The DNA in nuclear chromatin is packaged into nucleosomes, which consist of 146 DNA base pairs 
wound around bundles of eight core histone proteins (often compared to a thread around a spool). In 
its inactive state, chromatin is tightly wound and compact, and as a consequence, DNA is not accessible 
for transcription. Modification of the nucleosome by a variety of processes selectively exposes 
segments of DNA (typically in promoter regions), and makes them available for transcription.  Such 
selective transcription allows tissue and context specific expression of genes, despite a near-universal 
DNA sequence in all cells of a single individual.  
 
Such modulation of gene expression can be effected either by modification of histone proteins 
(typically in exposed segments called tails), or by modifying DNA directly. Such modification, which 
collectively underlies epigenetic regulation, modifies nucleosome chemistry through variable 
methylation (either of DNA or histone tails; Box 1), or acetylation or phosphorylation (typically of 
histone tails). The exposure of segments of DNA (and hence accessibility their accessibility for 
transcription) can also be modulated by other factors such as non-coding RNA (ncRNA) segments 
(Box 2), which regulate histone modifying enzymes; or by remodelling complexes which slide DNA 
on the underlying histone spool, and make segments of DNA more or less accessible for transcription. 
 
In TBI, these epigenetic processes could impact variability in injury susceptibility, the intensity of the 
pathophysiological response, response to therapies, the rate and extent of recovery, the development 
of post-traumatic neurodegeneration, and the hereditable consequences of injury.  The following 
manuscript focuses on DNA methylation as a key epigenetic processes that is emerging as important 
in TBI pathophysiology:  
 
Figure 1 
 
  
Box 1: DNA Methylation and Histone Modification – Two Sides of the Same Coin?  
The DNA in chromatin is packaged into nucleosomes, which consist of 146 DNA base pairs wound 
around bundles of eight (two units of H2A, H2B, H3 and H4) core histone proteins. Modification of 
the nucleosome by a variety of processes, allows selective accessibility of segments of DNA for 
transcription (typically in promoter regions), thus providing tissue and context specific expression of 
genes from a near-universal DNA sequence in all cells of a single individual. Such modifications can 
affect either the histone proteins (typically in exposed segments called tails), or by modifying the DNA 
directly.  
 
Histone proteins can be covalently modified in at least 67 different ways, and the specific combination 
of these modifications determines the ‘histone code’.4 Subsequently, this ‘code’ mediates specific 
protein–protein interactions contributing to short and long-term regulation of transcription, 
representing a form of cellular memory.5 This basic premise provides a mechanism by which alterations 
to histone proteins can result in epigenetic mechanism of gene regulation. When methyl binding 
proteins (MBPs) from the methyl-CpG binding domain (MBD) interact with methylated DNA sites in 
gene promoters they initiate a series of events, including recruitment of histone-modifying enzymes, 
deacetylation of histone protein tails, and chromatin condensation around the gene promoter.6 
Consequently, the methylation of DNA results in the deacetylation of histones and as such there is a 
compounded inhibitory effect on transcription.7  
 
Conversely, histone methylation can result in DNA methylation. For example, H3K27Me3, a 
trimethylated lysine residue at position 27 in histone H3, is associated with aberrant de novo DNA 
methylation. H3K27Me3 interacts with a DNA repression protein (the Polycomb complex), which, in 
association with another protein (EZH2), promotes DNMT-1 recruitment to the target chromatin 
complex, and results in DNA methylation.8 Direct evidence of changes in this complex interaction in 
TBI is still lacking and the functional importance is still unclear. One suggestion is that through this 
bidirectional crosstalk, epigenetic information from histone modifications is translated into a more 
stable record in the form of DNA methylation.  
 
Another hypothesis is that the direct interaction between MBPs and histone deacetylases, via a calcium-
dependent pathway, may represent one link between primary injury and late pathophysiology in TBI, 
at least in experimental models. However, there is also evidence to suggest that this calcium-mediated 
induction of specific genes may be entirely separate from the DNA methylation mechanism discussed 
thus far, and may actually be solely based on histone modifications. Both variants of the calcium-
mediated epigenetic-modification based pathway for early gene induction are described in figure 2.   
 
 
 
  
Box 2: DNA Methylation and Non-coding RNA  
Only 1–2% of the transcripts produced by genome transcription encode proteins. The functional 
consequences of the remaining noncoding ribonucleic acid (ncRNA) transcripts are poorly understood, 
yet they are associated with a variety of human diseases.15 The relationship between ncRNA and DNA 
methylation is best understood through the action of micro ribonucleic acids (miRNAs; small ncRNAs 
between 20–22 base pairs in length), which interact with specific messenger ribonucleic acids (mRNAs) 
to silence their expression post-transcriptionally. It is thought that some of these miRNAs 
downregulate the expression of DNMT, resulting in DNA hypomethylation.16  
 
In one in vitro model of focal ischemia, miR-29c levels decreased two-fold after oxygen-glucose 
deprivation (OGD), relative to controls. However, pretreatment with pre-miR-29c increased post-
OGD level of miR-29c three-fold, and halved cell death. Therefore, in vitro, miR-29c appears to be a 
pro-survival factor, possibly via its inhibition of DNMT-3A, and its absence after ischemic injury seems 
to promote cell death.17 Recently miR-29 a, b, and c have been shown to be down-regulated after TBI. 
It is possible that the interactions between ncRNA and DNA methylation observed in models of 
ischemia, suggesting a pro-survival action for MiR-29c, could also be true of TBI, however this 
proposition requires additional investigation.18 
 
Alternatively, the functional consequence of altered microRNA expression may be mediated via 
changes to mitochondrial function. Support for this proposition comes from the demonstration that 
microRNAs can regulate aspects of mitochondrial function (including mitochondrial gene expression 
associated with apoptosis and oxidative stress responses),19 and the data that mitochondrial function 
in TBI models can be modulated by changes in miRNA levels, as shown by Wang et al.20 As such, a 
growing area of interest is DNA methylation at the level of mitochondrial DNA, and how we might 
be able to produce novel therapies via modulation of the mitochondrial DNA methyltransferase 
enzymes.21,22 
 
 
 
Mechanisms of DNA methylation and demethylation 
The process of DNA methylation occurs predominantly at cysteine bases, which are converted to 5-
methylcytosine. In mammals, methylation targets cytosine bases that exist as part of a CpG (cytidine-
phosphate-guanidine) dinucleotide.23 Long stretches of DNA that are densely populated by CpGs are 
described as CpG islands (CpGIs), and are most commonly found in the proximal promoter region of 
genes.24 These genes are often associated with house-keeping functions including gene expression 
mechanisms, DNA replication in the nucleus, metabolism, and cell cycle control.7 The role of non-
CpG associated methylation is still controversial, and its functional consequences are poorly 
understood.25  In CpG islands, DNA methylation directly prevents the necessary factor and regulatory 
units from accessing the gene promoter,26 thereby inhibiting gene transcription. The process of DNA 
methylation and de-methylation are carried out by specific enzymes, the activity of which has been 
shown to change in experimental models of neural injury.  
 
DNA Methyltransferases (DNMT-1/3A/3B)  
The DNMT family of enzymes carry out the process of DNA methylation. DNMT-3B is 
predominantly expressed in embryonic and neural precursor cells while DNMT-3A is principally 
expressed later in development, in maturing neurons, oligodendrocytes, and astrocytes.27,28 DNMT-1 
is expressed in post-mitotic CNS neurons, and serves to institute and preserve the high local levels of 
DNA methylation.21 Essentially, DNMT-3A/B can be thought of as the de novo methyltransferases, 
whilst DNMT-1 maintains methylation status. 
 
Ten-eleven Translocation Methylcytosine Dioxygenase  
The ten-eleven translocation methylcytosine dioxygenase (TET) family of proteins has been proposed 
as a viable mechanism for active demethylation.29 Bailey and colleagues demonstrated that exposure to 
simulated free-field blast exposure, at 10 and 23 PSI resulted in significantly increased TET2, but not 
TET1 expression in the prefrontal cortices and hippocampi of male Sprague Dawley rats.30 Moreover, 
these changes were correlated with incrementally greater levels of global hypomethylation compared 
to shams. However, three recent loss-of-function mutation experiments demonstrate incongruent 
results regarding the effects of TET2 on DNA methylation status.31-33 An alternative explanation, is 
that TET2 could be preventing protracted inflammation by suppressing macrophage IL-6 expression, 
via the recruitment of histone deacetylase 2 (HDAC2) and histone deacetylation (a DNA methylation 
independent mechanism).34 Therefore, the increased inflammation associated with higher blast 
pressures also explains the observed increase in TET2 expression.  
 
Growth arrest and DNA-damage-inducible protein (GADD45) 
GADD45 has been identified as a mediator of active DNA demethylation.35 The potential relevance 
of such this process to neurotrauma can be inferred from demonstration that peripheral nerve injury 
decreases the repressive methylation of the GADD45a promoter.36 Intriguingly, systemic folate 
therapy, in a model of combined spinal and nerve injury, increases methylation of the GADD45a 
promoter at 12 of its 18 CpG sites, restores its methylation levels to baseline, and promotes spinal 
regeneration.37 Based on these findings, it would be of great interest to see whether GADD45 might 
also play a role in active demethylation in experimental models of TBI. 
 
DNA Methyltransferases in TBI: Temporal, regional, and cellular patterns and functional 
implications 
Whilst the action of the DNA methyltransferases is relatively well understood in non-pathological 
circumstances, the impact and action of these enzymes in pathological circumstances is not well 
understood. The following discussion addresses some issues that are of direct or indirect relevance to 
TBI. 
DNA methylation changes in acute TBI 
DMNT-1 expression is upregulated following a controlled cortical impact injury (CCI) in the prefrontal 
cortices and hippocampi of both male and female Sprague Dawley pups (21 days old at trauma, 47 at 
sacrifice).38 However, these brain areas have several different roles, and cell types, making it impossible 
to infer the functional relevance of this upregulation, especially given the evidence (discussed later) that 
genes are differentially affected, and can display either hyper- or hypo-methylation post-injury.39  
Moreover, the global increase described by the previous study may be misleading, as more targeted 
analysis of DMNT-1 in pathological and non-pathological circumstances shows specific cellular and 
intra-cellular patterns of expression. Lundberg et al showed that DMNT-1 expression in normal rat 
cortex, is almost exclusively nuclear.40 However, some peri-ventricular cells (in both injured and 
uninjured rat brain) co-express nestin and DNMT1 in both nucleus and cytoplasm.40 Given that nestin, 
an intermediate filament protein, is a histological marker of neuronal precursor cells,41 its co-
localisation with cytoplasmic DNMT-1 suggests that the enzyme may play a role in neuronal 
differentiation.  
Cellular specificity of changes in DNA methylation 
Subsequently, Lundberg and colleagues described the impact of TBI on the expression of DMNT-1. 
At four days post-CCI in male Sprague Dawley rats, peri-lesional nestin, glial fibrillary astrocytic protein 
(GFAP), and neuronal nuclei (NeuN) stained cells demonstrated both nucleic and cytoplasmic 
localization of DNMT-1.40 GFAP is a known histological marker for astrocytes.41 There was no 
corresponding cytoplasmic localization of DNMT-1 in microglial cells. The quantity of cytoplasmic 
DNMT-1 declined at each subsequent time point, and was almost completely absent by 14 days post-
injury.40 Based on the illustration of both a spatial (nuclear to cytoplasmic shift) and temporal 
(cytoplasmic immunoreactivity absence by day 14) relationship between TBI and DNMT-1, it may be 
that a similar process to physiological differentiation is induced in peri-lesional reactive astrocytes post-
injury.40 Assuming that the presence of nestin implies that the cells have transitioned to a less 
differentiated state, the JAK/STAT pathway is may provide a plausible link in this process. DNA 
methylation status is thought to control the timing of astrocyte differentiation, through inhibition of 
STAT activity. Moreover, in the developing CNS, global hypomethylation it thought to promote active 
chromatin remodelling and expression of astroglial marker genes, manifesting as precocious astroglial 
differentiation.42 Thus, Lundberg and colleagues argue, DNMT1 re-localization may induce expression 
of specific genes in the JAK-STAT pathway that are critical in astrocyte differentiation,40 specifically 
through increased JAK-STAT signalling, as well as demethylation of the STAT binding element within 
the GFAP promoter.42 Therefore, DNMT1 re-localization could contribute to the epigenetic 
reprogramming of in situ reactive astrocytes, as a result of the brain trauma, explaining the persistence 
of astrogliosis.42  
Since DNA methylation is important in the regulation of cell-specific gene transcription, it is 
unsurprising that neurons and glia demonstrate differing methylation patterns under basal condition.43 
In a blast-exposure model (equal to 10.8 PSI), Haghighi and colleagues identified 1807 cytosine sites 
where hyper- and hypo-methylation followed 8 months post TBI, in the prefrontal cortex of 10 week-
old male Long Evans hooded rats. They demonstrated that methylation status varied in a wide variety 
of different genes in neurons and glia.39 These sites corresponded to 837 genes in the rat genome, of 
which 458 were specific to proteins found exclusively in neurons and are associated with cell death, 
growth, proliferation, and nervous system development. The remaining 379 altered genes were specific 
to proteins found exclusively in glia, and are associated with: enrichment in cancer, cellular growth and 
proliferation, as well as nervous system development and function. Notably, 92 of affected genes have 
been previously implicated in neurological disease pathogenesis, and 39 in neuropsychiatric disorders. 
The only other study directly examining DNA methylation following TBI found, in an otherwise 
normal rat brain library, evidence that the hypomethylation was localized to a subpopulation of reactive 
microglia.44 The latter study utilized a weight-drop contusion model in 8-9 week-old Lewis rats, and 
examined contused somatosensory cortex at 24, 48, 96 or 144 hours after brain injury.  
 
Whilst apparently incongruous, the differences in results from these studies may be attributed to 
differences in brain region examined (pre-frontal vs. somatosensory cortex), traumatic brain injury 
model (simulated blast vs. weight drop contusion), and time from exposure to analysis (hours/days vs. 
8 months).  Further, methodological factors may account for some of the differences observed. One 
of the limitations of simple bisulfite sequencing is that the process is unable to distinguish between 5-
methylcytosine (the target), and 5-hydroxymethylcytosine: the product of a TET protein mediated 
reaction.45 TET2 is thought to be important in resolving inflammation by suppressing IL-6,34 which is 
known to be produced by macrophages/microglia. It is plausible that the significant increase in 
qualitatively observed methylation in the Zhang study is due to the inclusion of 5-
hydroxymethylcytosine labelling,44 which fits with the localization in the microglial sub-population. 
This is especially convincing when we consider that the administration of dexamethasone, an anti-
inflammatory agent, led to the reduced levels of the hypomethylation, in a dose-dependent manner.44 
Reduced inflammation would mean less TET2 is required to resolve the inflammatory response, and 
therefore there would be fewer TET protein mediated alterations to the DNA. The Haghighi study 
utilized a specific variant of the TET assisted bisulfite sequencing method developed by Yu et al. 
capable of labelling just the intended target.39,46,47 Had the updated form of bisulphite sequencing not 
been utilized, they might have produced similar results to Zhang et al.,44 as the modifications by the 
TET proteins would have resulted in an artificially high level of DNA methylation in the microglial 
DNA profile. 
 
DNA Methylation and TGF-β 
Epigenetic methylation causes interesting changes in the biological pathway of transforming growth 
factor β (TGF-β), a cytokine that demonstrates significantly increased activity in neuronal cells, but not 
in glia, after blast-related TBI (see Haghighi et al., 2015).39 A recent cortical controlled impact model 
study using 8 week old C57BL/6 mice also demonstrated increased activity in this pathway, 1,3, and 7 
days post-traumatic injury, specifically in the forebrain subventricular zone and the hippocampal 
dentate gyrus, brain areas associated with neurogenesis.48 Normally, TGF-β signaling has a role in cell 
proliferation, synaptic transmission and adult neurogenesis.49,50 The functional consequences of 
upregulation of the TGF- β pathway is currently under investigation.51,52 However, it remains unclear 
whether upregulation of this pathway post-injury represents a part of the recovery process, or if TGF-
β1 contributes to CNS scar formation,53 prevents regeneration, and contributes to late pathophysiology. 
The interaction of TGF-β1 and the JAK-STAT pathway in promoting astrogliosis is recognized,54 but 
no specific data are available in the context of TBI.  
 
DNA Methylation and Neurodegeneration  
Epidemiological studies suggest that TBI may be an important epigenetic risk factor for Alzheimer’s 
disease (AD), although this remains a contentious subject, especially with regards to the mild TBI 
population.55 Two examples suggest that DNA methylation might elucidate the pathobiology behind 
this epidemiological link. Firstly, evidence from a rodent study (12-14 month old female Sprague-
Dawley rats)56 suggests that TGF-β, which is thought to be increased post-traumatic injury,39,48 
increases expression of amyloid precursor protein (APP) and deposition of beta amyloid (Aβ), both of 
which are implicated in the pathogenesis of Alzheimer’s disease.56 Another potential link between TBI 
and AD is based on recent in-vitro descriptions of DNA methylation in microglia cell lines as an 
important influence on the expression of genes associated with Alzheimer’s disease pathology, 
including beta secretase 1 (BACE1) and Presenilin 1.57-59 Both hypotheses are relatively nascent and 
require further research to demonstrate how the effect achieved following the primary insult is 
sufficiently long lived to the produce the delayed presentation of dementia.  
 
A potential role in post-traumatic epilepsy: Insights from ischemic brain injury 
Although TBI and ischaemia are not identical,60 neuronal responses in ischaemia provide additional 
mechanistic insights into the potential role of DNA methylation in TBI. For example, an ischemia-
reperfusion injury (IRI) in gerbils results in rapid reductions in DNMT1 activity in pyramidal (but not 
non-pyramidal) cells. Five days post-IRI DNMT1 immunoreactivity was localized to GABAergic 
interneurons, and astrocytes, but not microglia,61 a finding concordant with some of the data in TBI, 
and suggesting that glial cells can undergo epigenetic modification in response to, or as a result of 
injury. Furthermore, the specificity of expression in GABAergic neurons suggests potential switching 
from from the normal post-natal expression of the type 2 inwardly directed Na+/K+/2Cl- co-
transporter (NKCC2),62 to the type 1 cotransporter (NKCC1; which is more readily epigenetically 
modulated,63 preferentially expressed during prenatal development, and results in a depolarizing 
response).64 Indeed, axotomy, ischemia and excitotoxicity, all of which mechanisms are recognized in 
TBI, are associated with changes in intracellular Cl- concentrations thought to be caused by a reversion 
to predominantly NKCC1 expression.65,66  DNMT1 expression in GABAergic interneurons following 
neural injury could thus change neuronal excitability, and link primary and secondary injury in TBI. 
Indeed, Wang et al have shown that NKCC1 upregulation appears to mediate post-traumatic seizures, 
and that inhibition of this pathway by genetic deletion or pharmacological inhibition suppresses TBI-
induced seizures.67 Furthermore, this seizure pathway may be additionally driven by TGF- β expression, 
suggesting a critical nexus for epigenetic mechanisms associated with TBI. 
 
DNA Methylation in circadian rhythms and sleep physiology 
Common symptoms following TBI include sleep disturbances and depression.68 Sleep deprivation 
may be related to reduced melatonin levels observed post-TBI and contribute to impaired psychiatric 
and neurological recovery.69 In a blast-model of TBI, expression of the Aanat gene was modestly 
decreased as a result of increased methylation.39 The Aanat gene encodes an enzyme (Aralkylamine 
N-acetyltransferase) involved in the conversion of serotonin to melatonin, which is important in 
entrainment of the circadian rhythms, and both the gene and the pathway have also been linked to 
depression susceptibility.70,71 TBI-specific epigenetic changes, such as Aanat suppression, might 
disrupt the normal circadian patterns explaining why symptoms such as sleep disruption are 
associated with TBI. Light induced histone phosphorylation is also known to regulate the function of 
the central circadian pacemaker, the suprachiasmatic nucleus through activation of immediate early 
genes including BDNF.72 Furthermore, such histone modifications can alter rhythmic activity in other 
organs in a manner similar to that of imprinted pathologies.73 Further exploration of these links 
between TBI and epigenetics could elucidate pathophysiology and identify potential new therapeutic 
targets in TBI. 
 
Clinical applications: therapy and prognostication 
While there are no current therapies for TBI that target epigenetic pathways, several potential examples 
suggest pathways for such development. 
 
Lithium shows several potentially beneficial effects in TBI including the induction of autophagy and 
the ability to prevent excess inflammation by inhibiting microglia activation.74 However, lithium may 
also modulate epigenetic mechanisms in the brain, as suggested by its role bipolar disorder (BD), where 
it may restore or increase the levels of BDNF and so reduce the repressive hypermethylation of the 
BDNF promoter region.75 A similar mechanism might be activated with lithium treatment post-TBI. 
The DNA methylation inhibitor, zebularine, which proved capable of reducing the extent injury in an 
ischemia model,76 corroborating findings that a partial genetic deletion of DNMT-1 enzyme improved 
outcome in experimental stroke.77 
  
Folic acid is a methyl donor substrate, and a vital ingredient in the production of cellular S-adenosyl-
methionine, which in turn is required by DNMTs. Given that folate administration can repress the 
demethylating action of growth arrest and DNA damage-inducible gene 45 alpha (GADD45),36 and its 
ability to suppress DNMT-3A/3B, but not DNMT-1, and thereby restore baseline methylation status, 
folate may have a therapeutic role post TBI.37 Evidence for the efficacy of folate as a pharmacological 
intervention can be seen in a recent piglet model of pediatric TBI, which found folate supplementation 
led to significantly improved functional recovery as compared to controls at day one post head injury 
(although these gains did not persist to day four).78 Additional evidence is needed, but the safety of 
folate supplementation makes this an attractive early target for a clinical trial, with an explanatory arm 
that demonstrates the mechanistic basis for any benefit seen.  
 
A better understanding of which genes undergo epigenetic changes, how this alters their function, and 
the relationship to TBI pathology, may allow development of a prognostic stratification based on these 
epigenetic modifications.79 Whilst we have highlighted several potential candidates linking epigenetic 
alterations to TBI pathophysiology, our current understanding of individual variation post-TBI remains 
insufficient to determine whether these factors might be of prognostic significance.  
 
Finally, much of the discussion thus far has focused on the changes that occur downstream of the 
DNA methylation. However, understanding the biochemical process that precedes the epigenetic 
modifications, may allow us to identify potential interventions to prevent or modify them, before they 
can become detrimental to the individual’s health. The evidence available suggests that calcium plays a 
pivotal role in linking trauma to the epigenetic changes described previously. Figure 2 illustrates how 
calcium related change that occur due to trauma can lead to both DNA methylation and histone 
modifications.  
 
Practical Considerations 
Extrapolations from other pathologies: a cautionary note 
Other publications, and earlier sections of this manuscript, have drawn on knowledge of physiological 
mechanisms of epigenetic modulation, and its alteration in diseases other than TBI, to provide a basis 
for further studies.  While there may be substantial commonalities amongst diseases, it is important to 
recognize potential discordances. Debski and colleagues investigated DNA methylation patters in three 
models of acquired epilepsy, of which one was TBI, and found that they did not share any evidence of 
a common epigenetic signature, but instead appeared to suggest that different epileptogenic (biological) 
processes prevailed in each model.80 As such, it is of paramount importance that we exercise caution 
in transferring epigenetic models of pathobiology from other diseases to TBI.  
 
Confounding Factors 
Recruitment bias in epigenome wide association studies (EWAS) is a key issue for future studies.81 
Particular confounds may arise from socioeconomic/environmental effects on DMNT-1 expression. 
Calorie restriction and dietary fat content have been incidentally noted to have significant effects on 
DMNT-1 expression, which vary with sex in animal models.82  It would be important to explore similar 
effects in humans TBI, particularly given the recent demonstrations of diet-dependent (and potentially 
heritable) epigenetic changes.83 If confirmed, this phenomenon has important implications for sample 
size, recording of socioeconomic and dietary history, and the use of best practice statistical methods 
such as multiple testing corrections and mitigation of batch effects.81 
 
Temporality  
The reversible and therefore dynamic nature of epigenetic changes adds an additional layer of 
complexity to describing the changes that occur in response to pathology, since the temporal context 
(e.g. time since trauma) in which those changes have occurred is of vital importance. Point estimates 
of epigenetic variation/alteration fail to capture that additional complexity, and thus, could lead to 
spurious conclusions about the role of epigenetic modifications. Only very recently have studies begun 
to characterize the temporal profiles of these changes.84 
 
 
Routes to human translation 
Access to brain tissue: One of the key obstacles in epigenetic research, in the context of brain injury, 
is the difficulty in securing viable tissues samples in living individuals for sequencing. In the context of 
ethically approved research, it may be possible to harvest cerebrospinal fluid, or brain tissue during 
routine clinical care for epigenetic analysis. However, such sampling is biased to either the early period 
after TBI, or to terminal pathophysiology in autopsy specimens. Control (i.e. non-TBI) tissue may, 
paradoxically, be also more difficult to access in this context. Tissue from spontaneously aborted or 
terminated pregnancies,85 can provide insight into DNA methylation during the early stages of human 
development and even the impact of specific types of pathology, like ischemia, on the epigenome, but 
cannot strictly be used as control samples for TBI studies.  
 
Imaging epigenetic changes in vivo: Positron emission tomography (PET) using [11C]Martinostat, an 
imaging probe selective for specific classes of histone deacetylases (HDACs) most associated with 
regulating neuroplasticity, has been described, and allows in vivo quantification of HDAC activity in 
vivo in humans.86 Although this technology is still young, and therefore can only be used to answer very 
specific hypothesize, it represents a trend toward non-invasive measurement of epigenetic 
modifications which are important given the constantly fluctuating nature of the changes.84   
 
Circulating DNA analysis: Another non-invasive method that has become increasingly relevant in the 
last 5 years is the analysis of cell free circulating DNA.  Examination of both serum and CSF samples 
for DNA methylation patterns have been found to be useful in identifying tissue specific cell death. A 
greater understanding of brain cell type specific methylation patterns may allow for even more specific 
monitoring beyond the authors description of gross measurement of brain cell death post-traumatic 
brain injury.87 However, it should be noted that the potential usefulness of this method is still a matter 
of debate. Using unsupervised clustering and principal component analysis of eye tissue and peripheral 
blood sample epigenetic profiles, Hewitt and colleagues demonstrate that the origin of the tissue 
appears to be the main driver of variation in methylation patterns.88 Moreover, there was only limited 
covariation between the blood and specific eye tissues. Conversely, other studies have demonstrated 
that when a specific gene is known to have functional/diagnostic/treatment-related relevance it may 
be possible to too look for promotor methylation changes in such peripherally obtained samples, as 
has been done with serum and CSF probes for MGMT promotor methylation in glioma patients.89  
 
Assessing epigenetic changes in the host response after TBI: While the discussions above have focused 
on assessment of epigenetic changes in the brain, it is important to recognize that TBI results in a 
substantial host response which involves both innate and adaptive immunity.90 As in many other 
diseases, these changes may be epigenetically driven, and potentially contribute to both early and late 
pathophysiology following TBI. Examination of epigenetic changes in peripheral blood mononuclear 
cells (PBMCs) can be confounded by changes in cell populations, but if these can be mitigated by cell 
sorting, epigenomic analysis of peripheral immune cells may provide a tractable, and potentially 
important tool in understanding the late consequences of TBI.91,92 
 
Conclusion 
The role of epigenetic changes, and particularly DNA methylation, in TBI-related pathology is 
increasingly being explored. The experimental literature has identified many epigenetic changes which 
in turn lead to changes in neuronal and glial function. For example, changes in DNMT-1 
immunoreactivity altered methylation status of glia and neurons, DNA methylation and transcription 
of noncoding RNA. These epigenetic alterations may provide a mechanism for longer-term changes 
and even hereditable consequences. However, the mechanisms of these processes as well as the impacts 
of different injury patterns and individual variation on epigenetic response are not yet understood fully. 
There is a strong case for further work that aims to explain the basic pathobiology of epigenetic 
modification in TBI, rather than epigenome level associative studies, as a keen understanding of the 
former is necessary to interpret the results of the latter. Key outstanding questions are presented in 
table 1. The full extent of how epigenetic change contributes to or mitigates secondary brain injury 
remains unclear, and is an important area of future research. 
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